Nucleostemin expression in invasive breast cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Kobayashi, Takayuki ^a,b   Masutomi, Kenkichi ^c   Tamura, Kenji ^d   Moriya, Tomoyuki ^a   Yamasaki, Tamio ^a   Fujiwara, Yasuhiro ^d   Takahashi, Shunji ^b   Yamamoto, Junji ^a   Tsuda, Hitoshi ^a,d  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NUCLEOSTEMIN; PROTEIN P53; REGULATOR PROTEIN; UNCLASSIFIED DRUG; CELL PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; BREAST SURGERY; CANCER TISSUE; CLINICAL FEATURE; COHORT ANALYSIS; DISTANT METASTASIS; HISTOPATHOLOGY; INVASIVE BREAST CANCER; LYMPH NODE METASTASIS; PROTEIN ANALYSIS; SURVIVAL TIME; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GTP-BINDING PROTEINS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899097367     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-215     Document Type: Article

References (37)

1. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005, 10(Suppl 3):20-29.
2. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?. J Natl Cancer Inst 2010, 102(7):456-463. 10.1093/jnci/djq029, 3298957, 20220104.
3. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006, 124(6):1111-1115. 10.1016/j.cell.2006.03.011, 16564000.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001, 414(6859):105-111. 10.1038/35102167, 11689955.
5. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5(4):275-284. 10.1038/nrc1590, 15803154.
6. Tsai RY, McKay RD. A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev 2002, 16(23):2991-3003. 10.1101/gad.55671, 187487, 12464630.
7. Bernardi R, Pandolfi PP. The nucleolus: at the stem of immortality. Nat Med 2003, 9(1):24-25. 10.1038/nm0103-24, 12514717.
8. Ye F, Zhou C, Cheng Q, Shen J, Chen H. Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 2008, 8:108. 10.1186/1471-2407-8-108, 2387168, 18419830.
9. Fan Y, Liu Z, Zhao S, Lou F, Nilsson S, Ekman P, Xu D, Fang X. Nucleostemin mRNA is expressed in both normal and malignant renal tissues. Br J Cancer 2006, 94(11):1658-1662. 2361296, 16670719.
10. Liu RL, Zhang ZH, Zhao WM, Wang M, Qi SY, Li J, Zhang Y, Li SZ, Xu Y. Expression of nucleostemin in prostate cancer and its effect on the proliferation of PC-3 cells. Chin Med J (Engl) 2008, 121(4):299-304.
11. Cada Z, Boucek J, Dvorankova B, Chovanec M, Plzak J, Kodets R, Betka J, Pinot GL, Gabius HJ, Smetana K. Nucleostemin expression in squamous cell carcinoma of the head and neck. Anticancer Res 2007, 27(5A):3279-3284.
12. Malakootian M, Mowla SJ, Saberi H, Asadi MH, Atlasi Y, Shafaroudi AM. Differential expression of nucleostemin, a stem cell marker, and its variants in different types of brain tumors. Mol Carcinog 2010, 49(9):818-825.
13. Zhang G, Zhang Q, Yin L, Li S, Cheng K, Zhang Y, Xu H, Wu W. Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues. J Cancer Res Clin Oncol 2010, 136(4):587-594. 10.1007/s00432-009-0693-2, 19823871.
14. Tamase A, Muraguchi T, Naka K, Tanaka S, Kinoshita M, Hoshii T, Ohmura M, Shugo H, Ooshio T, Nakada M, Sawamoto K, Onodera M, Matsumoto K, Oshima M, Asano M, Saya H, Okano H, Suda T, Hamada J, Hirao A. Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A 2009, 106(40):17163-17168. 10.1073/pnas.0905016106, 2761321, 19805150.
15. Okamoto N, Yasukawa M, Nguyen C, Kasim V, Maida Y, Possemato R, Shibata T, Ligon KL, Fukami K, Hahn WC, Masutomi K. Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A 2011, 108(51):20388-20393. 10.1073/pnas.1015171108, 3251068, 21730156.
16. Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis. Breast Cancer Res Treat 2010, 123(3):733-745. 10.1007/s10549-009-0672-y, 20020198.
17. Nakajima TE, Yoshida H, Okamoto N, Nagashima K, Taniguchi H, Yamada Y, Shimoda T, Masutomi K. Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma. Cancer Sci 2012, 103(2):233-238. 10.1111/j.1349-7006.2011.02142.x, 22050045.
18. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.
19. Yoshida R, Fujimoto T, Kudoh S, Nagata M, Nakayama H, Shinohara M, Ito T. Nucleostemin affects the proliferation but not differentiation of oral squamous cell carcinoma cells. Cancer Sci 2011, 102(7):1418-1423. 10.1111/j.1349-7006.2011.01935.x, 21443540.
20. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100(7):3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
21. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445(7123):106-110. 10.1038/nature05372, 17122772.
22. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445(7123):111-115. 10.1038/nature05384, 17122771.
23. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004, 432(7015):396-401. 10.1038/nature03128, 15549107.
24. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1(5):555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
25. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1(3):313-323. 10.1016/j.stem.2007.06.002, 18371365.
26. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S. Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993, 143(3):867-874. 1887197, 8362982.
27. Tempfer C, Losch A, Heinzl H, Hausler G, Hanzal E, Kolbl H, Breitenecker G, Kainz C. Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur J Cancer 1996, 32A(11):2023-2025.
28. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008, 99(8):1285-1289. 10.1038/sj.bjc.6604664, 2570510, 18781171.
29. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao S. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008, 98(8):1389-1397. 10.1038/sj.bjc.6604307, 2361715, 18349830.
30. Marechal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Deviere J, Salmon I, Van Laethem JL. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 2009, 100(9):1444-1451. 10.1038/sj.bjc.6605020, 2694427, 19352387.
31. Davidoff AM, Herndon JE, Glover NS, Kerns BJ, Pence JC, Iglehart JD, Marks JR. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991, 110(2):259-264.
32. Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 1993, 169(1):27-34. 10.1002/path.1711690106, 8433213.
33. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994, 57(1):1-9. 10.1002/ijc.2910570102, 8150526.
34. Ma H, Pederson T. Depletion of the nucleolar protein nucleostemin causes G1 cell cycle arrest via the p53 pathway. Mol Biol Cell 2007, 18(7):2630-2635. 10.1091/mbc.E07-03-0244, 1924810, 17494866.
35. Dai MS, Sun XX, Lu H. Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol Cell Biol 2008, 28(13):4365-4376. 10.1128/MCB.01662-07, 2447154, 18426907.
36. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC, Aldaz CM. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res 2000, 60(21):5977-5983.
37. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(19):10869-10874. 10.1073/pnas.191367098, 58566, 11553815.